|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest bearing time deposits | ||||||||||||||||||||
| Available-for-sale securities | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Loans, net of unearned income | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Federal Reserve and Federal Home Loan Bank Stock, at cost | ||||||||||||||||||||
| Foreclosed assets and other assets held for sale, net | ||||||||||||||||||||
| Interest receivable | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Cash value of life insurance | ||||||||||||||||||||
| Mortgage servicing rights | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Non interest bearing demand | ||||||||||||||||||||
| Interest bearing demand | ||||||||||||||||||||
| Savings | ||||||||||||||||||||
| Money market | ||||||||||||||||||||
| Time deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Repurchase agreements | ||||||||||||||||||||
| Federal Home Loan Bank advances | ||||||||||||||||||||
| Trust preferred securities | ||||||||||||||||||||
| Subordinated debt net of issuance costs | ||||||||||||||||||||
| Interest payable | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' Equity | ||||||||||||||||||||
| Common stock, no par value; 2026 - 10,500,000 shares authorized, 8,525,375 shares issued; 2025 - 10,500,000 shares authorized, 8,525,375 shares issued | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock, at cost; (2024 - 1,847,073 common shares; 2023 - 1,756,733 common shares) | ||||||||||||||||||||
| Treasury stock, at cost; (2026 - 2,269,383 common shares; 2025 - 2,249,417 common shares) | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity |
Loading...
